Experts shared the key data that stood out in GU oncology at the 2026 ASCO Annual Meeting.
|Videos|March 14, 2011
Dr. Alter on Kidney Cancer Drugs From 2005-2010
Author(s)Robert S. Alter, MD
Robert S. Alter, MD, Co-chief, Urologic Oncology, John Theurer Cancer Center, on kidney cancer drugs from the year 2005 to 2010.
Advertisement
Robert S. Alter, MD, Co-chief, Urologic Oncology, John Theurer Cancer Center, on kidney cancer drugs from the year 2005 to 2010.
Advertisement
Related to this article
The top 5 OncLive TV videos of the week cover insights in pancreatic cancer, non–small cell lung cancer, the cost and value of immunotherapy, and bladder cancer.
Matthew Galsky, MD, discusses the FDA approval of perioperative pembrolizumab plus enfortumab vedotin in MIBC.
Faculty reviewed data-driven advances in treatment intensification, sequencing, and emerging biomarkers across the prostate cancer and RCC continuums.
The top 5 OncLive TV videos of the week cover insights in bladder cancer, chronic myeloid leukemia, multiple myeloma, pancreatic cancer, and chronic lymphocytic leukemia.
Phase 2 data show adjuvant penpulimab significantly improves disease-free survival vs surveillance in very high-risk clear cell renal cell carcinoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves SimpleScreen CRC Blood-Based Screening Test for Average-Risk Adults
2
Sonesitatug Vedotin Improves Overall Survival in Second- and Later-Line CLDN18.2-Positive Gastric/GEJ Cancer
3
Volume, Biomarkers, and Cost Realities Guide ARPI Sequencing in Advanced Prostate Cancer
4
Updated Safusidenib Data Show Durable Responses in Grade 2 IDH1-Mutant Glioma
5